Lineage Cell Therapeutics Presents at H.C. Wainwright 27th Annual Global Investment Conference

Lineage Cell Therapeutics presented at H.C. Wainwright's 27th Annual Global Investment Conference. The company's CEO, Brian Culley, discussed the company's mission to manufacture and deliver specific cell types to address diseases where cell loss causes the condition. The focus is on dry age-related macular degeneration, where RPE cells are lost, and the company manufactures RPE cells in the lab to restore function in patients. The pipeline includes other neurological and ophthalmic conditions.

Lineage Cell Therapeutics, Inc. has announced the initiation of a new islet cell transplant program for Type 1 Diabetes (T1D). The company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establishing a production modality that can support the entire production process in a dynamic culturing system Lineage Cell Therapeutics, Inc. Initiates Cell Transplant Program in Type 1 Diabetes^[1].

The new program is a significant step towards commercializing islet cell therapy product candidates. Islet cell transplantation is a promising treatment for T1D, which affects millions of people worldwide. By manufacturing islet cells in a dynamic culturing system, Lineage Cell Therapeutics aims to overcome a major hurdle to the commercialization of this therapy.

The company's CEO, Brian Culley, presented at H.C. Wainwright's 27th Annual Global Investment Conference, discussing the company's mission to manufacture and deliver specific cell types to address diseases where cell loss causes the condition. The focus is on dry age-related macular degeneration, where retinal pigment epithelial (RPE) cells are lost, and the company manufactures RPE cells in the lab to restore function in patients Sanofi gets USFDA fast track designation for neovascular age-related macular degeneration gene therapy^[2].

The pipeline of Lineage Cell Therapeutics also includes other neurological and ophthalmic conditions. The company's commitment to innovation and addressing unmet medical needs positions it as a potential leader in cell-based therapies.